Cis-diamminedichloroplatinum(II) (cisplatin) is a well-known anti-tumor agent, and resistance of some cancer cell lines to this drug is associated with RP uS3 (RPS3), which activates the NF-κB pathway due to an extra-ribosomal function of the protein as a subunit of the NF-κB complex [92]. Here, NFKB1 is linked to cancer.